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The present study was designed to evaluate the acute and chronic antidepressant effect of genistein in combination with
amitriptyline inmice. Animals were divided into six groups (𝑛 = 6) for treatment withwater, genistein, or amitriptyline, either alone
or in combination for ten days. Animals were subjected to locomotor activity testing; tail suspension test (TST); and forced swim
test (FST) and immobility time was recorded on day one and day ten. Acute treatment of all treatment groups did not significantly
reduce the immobility time (𝑝 > 0.05). Chronic treatment of combination of genistein (10mg/kg) and amitriptyline (5mg/kg and
10mg/kg) significantly reduced the immobility time as compared to control group (𝑝 < 0.001) and was comparable to amitriptyline
alone (10mg/kg). However, no changes in anti-immobility activity in combination of subeffective doses of genistein (5mg/kg) and
amitriptyline (5mg/kg) were observed. Genistein at its standard dose (10mg/kg) rendered synergistic effects in combination with
subeffective dose of amitriptyline (5mg/kg) and additive effects in combination with therapeutic dose of amitriptyline (10mg/kg).
1. Introduction
Depression is the most common affective disorders (defined
as disorders of mood rather than disturbances of thought
or cognition); it may range from very mild conditions,
bordering on normality, to severe (psychotic) depression
accompanied by hallucinations and delusions.The emotional
symptoms of depression described by Diagnostic and Sta-
tistical Manual of Mental Disorders are lack of interest,
sadness, guiltiness, and suicidal thoughts while lack of sleep,
headaches, pain, sleep disorders, changes in appetite, gas-
trointestinal disorders, and changes in psychomotor function
are the physical symptoms of depression. Around 6.3 to 15.7%
of the world’s population is estimated to suffer depression
once in life according to World Health Organization Inter-
national Consortium of Psychiatric Epidemiology (WHO-
ICPE). Additionally, 7 to 12% inmen and 20 to 25% inwoman
are the estimation of lifetime prevalence of major depression
in adults [1, 2].
Tricyclic antidepressant like amitriptyline is chemically
heterocyclic compounds used effectively for treating depres-
sion since it acts as a serotonin-norepinephrine reuptake
inhibitor, thereby increasing the concentration of these trans-
mitters in the synapse. Since many side effects due to chronic
administration limit the therapeutic treatment, so it is neces-
sary to unveil new targeted drugs with the claim of a more
favourable tolerability and efficacy profile [3].
Natural compounds including genistein, a soy isoflavone,
have been suggested in treatment of depression. It is a poten-
tial molecule as legumes are part of traditional diets in many
regions of the world. However, studies conducted in patients
with depression are limited. A randomised controlled trial has
demonstrated that depression scores decrease significantly
after 1 and 2 years of genistein treatment in postmenopausal
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women [4]. Animal models are also useful to study the
antidepressant-like activity. Treatment of genistein 10mg/kg
for 14 days in ovariectomised rats has been shown to reduce
the immobility time, themarker of depression in forced swim
test [5]. Beside that, consumption of dietary genistein renders
a wide range of potential health benefits including alleviation
of menopausal symptoms, chemoprevention of breast and
prostate cancers, and cardioprotective effect [6, 7].
In the present study, we aimed to investigate the effect
of genistein in combination with amitriptyline administered
acutely and chronically on animal behaviour in tail suspen-
sion test (TST) and forced swim test (FST) and locomotor
activity testing inmice.We hypothesised that genisteinwould
potentiate the antidepressant effect of amitriptyline. Ulti-
mately, the combined therapy allows lower dose of amitripty-
line to be employed and hence reduces its magnitude of side
effects and may be effective in cases of treatment-resistant
depression.
2. Materials and Methods
2.1. Animals. Adult male albinomice (BALB/c strain) weigh-
ing 20–30 g were used in this study. They were housed
in group of 6 at a controlled temperature (25 ± 1∘C) and
humidity (50 ± 10%) with 12 h light/dark cycle (lights on
at 7:00 am) with free access to standard pellet and water.
Animals were used only once in each test. The experimental
protocol was approved by the Laboratory Animal Care and
Use Committee, International Medical University, Kuala
Lumpur, Malaysia.
2.2. Drugs and Treatment. Amitriptyline (Sigma-Aldrich) and
genistein (Sigma-Aldrich) were purchased from CHEMO-
LAB Supplies (Malaysia). All drugs were dissolved in reverse
osmosis (RO) water and administered 1 hour before test. All
test solutions were freshly prepared and administered orally
in a volume of 10mL/kg body weight for 10 days. Animals
were randomly divided into 6 groups (𝑛 = 6) as follows. The
doses were selected based on those reported in the literature.
All themice were administered orally one hour before the
locomotor activity testing; TST and FST were carried out on
day one and day ten as follows:
Group 1: [control]: RO water (0.5mL),
Group 2: [standard]: amitriptyline 10mg/kg,
Group 3: [standard]: genistein 10mg/kg,
Group 4: [test]: genistein 5mg/kg + amitriptyline
5mg/kg,
Group 5: [test]: genistein 10mg/kg + amitriptyline
5mg/kg,
Group 6: [test]: genistein 10mg/kg + amitriptyline
10mg/kg.
2.3. Locomotor Activity Testing. The locomotor activity was
measured on innate pretreated mice by an actophotometer.
Actophotometer functioned on photoelectric cells that were
attached in circuit with a counter. When the ray of light
dropping on the photocell was cut off by the animal, a count
was noted.These cutoffswere calculated for a period of 10min
and the numberwas used as a degree of the locomotor activity
of the animal [8].
2.4. Tail Suspension Test (TST). The TST was conducted
according to themethod of Steru et al. [9].Mice both acousti-
cally and visually isolated were suspended by their tail in the
TST apparatus (50 height × 45 width × 12 cm depths) on the
first day and tenth day of drug administration. The duration
of immobility was recorded for test period of 5 minutes. Mice
were considered immobile when they hung passively and
completely motionless.
2.5. Forced Swim Test (FST). According to the FST method
described by Porsolt et al., the mice were placed individually
into 5 L glass beakers filled with 15 cm height of water. The
water was changed frequently to eliminate fur, urine, and
excrement after each test was done.When the mice remained
floating in the water without struggling, making only mini-
mummovements of its limbs necessary to keep its head above
the water surface, they were considered to be immobile. This
was classified as induced depression. The total duration of
immobility was recorded during 5-minute test.The immobil-
ity periodwas calculated by subtracting total time (5minutes)
from time spent in escaping behaviour such as swimming and
climbing. Swimming was defined as movements throughout
the glass beaker and climbing was considered as upward-
directed movements of forepaws by the side of glass beaker.
Antidepressant drug treatment reduced the length of time
the animals remain immobile and increased the escaping
behaviour [10–12].
2.6. Statistical Analysis. All results were presented as mean ±
SEM and ∗∗∗𝑝 < 0.001, ∗∗𝑝 < 0.01, and ∗𝑝 < 0.05 were con-
sidered significant. Data were analyzed by one-way ANOVA,
followed by Dunnett’s post hoc test using Graph Pad Prism
version 5.0.
3. Results
Body weight was evaluated before and after 10 days of
treatment and weight gain is shown in Figure 1. Although
weight loss was observed in the combination of genistein
(10mg/kg) and amitriptyline (10mg/kg), there was no signif-
icant differences in body weight gain among all the treatment
groups (𝑝 > 0.05).
In locomotor activity, as per Table 1, amitriptyline
(10mg/kg) shows a nonsignificant increase, whereas genistein
significantly increases a locomotor activity alone and in com-
bination with different doses of amitriptyline, respectively
(𝑝 < 0.05; 𝑝 < 0.01; and 𝑝 < 0.001).
In TST, as shown in Figure 2, all treatment groups did not
alter the total immobility time as compared to control group
on the first day of experiment.
The behavioural effects after 10-day treatment are shown
in Figure 3. On 10th day, individual treatments of amitripty-
line (10mg/kg) and genistein (10mg/kg) produced significant
decrease in immobility time as compared to control group
(𝑝 < 0.05). The decrease in immobility time of genistein
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Table 1: Effects of the standard drugs and their combined treatments
on locomotor activity.
Treatment (dose, mg/kg, p.o.) Activity counts (s)
Normal control 165.36 ± 9.05
Amitriptyline 10mg/kg 67.03 ± 5.38
Genistein 10mg/kg 226.4 ± 12.35c
Genistein 5mg/kg + amitriptyline 5mg/kg 153.7 ± 13.27b
Genistein 10mg/kg + amitriptyline 5mg/kg 189.3 ± 10.14c
Genistein 10mg/kg + amitriptyline 10mg/kg 102.35 ± 14.12a
Values are expressed in mean ± SEM, where 𝑛 = 6.
a
𝑝 < 0.05, compared with normal control group.
b
𝑝 < 0.01, compared with normal control group.
c









































































































Figure 1: Effects of the standard drugs and their combined treat-
ments on body weight gain in mice after 10 days. Values represent
themean ± SEM (𝑛 = 6). Data were analyzed with one-way ANOVA
followed by Dunnett’s post hoc test.
was comparable to amitriptyline. Coadministration of genis-
tein (10mg/kg) with amitriptyline (5mg/kg and 10mg/kg)
significantly decreased the immobility time as compared to
control group (𝑝 < 0.001) and were comparable to standard
amitriptyline (10mg/kg) and genistein (10mg/kg) alone.
However, the combination of genistein and amitriptyline at
subeffective doses (5mg/kg) did not significantly reduce the








































































































Figure 2: Effects of the standard drugs and their combined treat-
ments on immobility time on 1st day. Values represent the mean ±
SEM (𝑛 = 6). Data were analyzed with one-way ANOVA followed
by Dunnett’s post hoc test.
In FST, on day one, mean immobility period was reduced
in animals treated with amitriptyline 10mg/kg alone, genis-
tein 10mg/kg alone, and combined use of genistein 5mg/kg
with amitriptyline 5mg/kg and genistein 10mg/kg with
amitriptyline 5mg/kg and genistein 10mg/kg with amitripty-
line 10mg/kg compared to control group but therewas no sta-
tistically significant difference in duration of immobility in all
groups of animals compared to animals in control group on
first day, Figure 4. After ten days of administration, decrease
in mean duration of immobility in all groups of animals
was found to be statistically significant comparable to that
of control groups, Figure 5. Genistein with dose of 10mg/kg
and amitriptyline with dose of 5mg/kg in combination group
showed most significant decrease in immobility period in
FST as compared to control group on day ten (𝑝 < 0.001).
4. Discussion
Acute treatment of amitriptyline does not produce antide-
pressant effect similar to previous findings [13]. This may
be due to delayed onset of action of antidepressant drugs
observed in clinical settings. However, some studies have
demonstrated that amitriptyline reduces the immobility time
in rodents on the first day of behavioural test [14, 15].
Nonetheless, amitriptyline administered chronically exerts
antidepressant activity. It is widely accepted thatmonoamines











































































































Figure 3: Effects of the standard drugs and their combined treat-
ments on immobility time on 10th day. Values represent the mean ±
SEM (𝑛 = 6). ∗∗∗𝑝 < 0.001, ∗∗𝑝 < 0.01, and ∗𝑝 < 0.05 were
considered significant as compared to control group. Data were
analyzed with one-way ANOVA followed byDunnett’s post hoc test.
reuptake inhibition is crucial for its action. By blocking
the serotonin and noradrenaline transporters, amitripty-
line increases the neurotransmitters in the synapse and
hence enhances neurotransmission [16]. Recent studies have
reported that it activates fibroblast growth factor receptor
signalling in glial cells which contribute to its antidepressant
action [17]. Several mechanisms involved in the mediation of
the antidepressant action after repeated treatment have been
proposed. It is suggested that chronic treatmentmay enhance
dopamine transmission in nucleus accumbens and also pro-
duce peptide of luteinizing hormone releasing hormone that
modulates affective disorder [18–20].
Consistent with previous findings [5, 21], acute treat-
ment of genistein does not exert antidepressant-like activity
but repeated treatment shows antidepressant effect which
is comparable to amitriptyline. Genistein has poor oral
bioavailability. It is rapidly eliminated from plasma and
excreted in the urine within 24 hours after single dose [6, 22,
23]. Hence, daily administration of genistein might increase
plasma concentration of genistein but should not expect a
dramatic increase in plasma level after 2-3 doses of treatment.
A six-month randomised controlled trial has shown that
plasma levels of genistein increase in first and sixth month









































































































Figure 4: Immobility time (sec) in mice in forced swim test. Values
represent the mean ± SEM (𝑛 = 6). All groups were compared with
vehicle control (one-way ANOVA followed by Dunnett’s test).
Chronic genistein (10mg/kg) in combination with ther-
apeutic doses of amitriptyline (10mg/kg) has significant
antidepressant activity as compared to control group and is
comparable to individual treatments. This suggests an addi-
tive effect at antidepressant dose of amitriptyline. On the
other hand, genistein (10mg/kg) in combination with subef-
fective doses of amitriptyline (5mg/kg) administered chron-
ically exerts antidepressant effect which is comparable to
individual treatments, suggesting synergistic effect at subef-
fective dose of amitriptyline. Nevertheless, subeffective dose
of genistein (5mg/kg) fails to augment antidepressant effect
of amitriptyline.
One of the side effects of tricyclic antidepressants is
weight gain. In this study, we failed to demonstrate body
weight gain in mice treated with amitriptyline. Studies in rats
have revealed that there is no linkage betweenweight gain and
amitriptyline treatment [25, 26]. Fromhere, we cannotmodel
the body weight changes of combination therapy in clinical
setting. Additionally, genistein in agreement with previous
report does not increase body weight in rats [5].
Genistein presents mainly in leguminous plants where 1
gram of soy protein contains 250𝜇g of genistein [7]. More-
over, 10mg/kg body weight of genistein for rats corresponds
with 600mg for a human [27]. The underlying mechanism
of genistein in depression remains unclear. Genistein shares
structural features with oestrogen-oestradiol-17𝛽 [7]. It can
penetrate the blood-brain barrier after administration and
bind differentially to 𝛼 or 𝛽 oestrogen receptors (OR) in














































































































Figure 5: Immobility time (sec) in mice in forced swim test. Values
represent the mean ± SEM (𝑛 = 6). ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and
∗∗∗
𝑝 < 0.001were considered significant; all groups were compared
with vehicle control (one-way ANOVA followed by Dunnett’s test).
the hippocampus [28]. Studies have concluded that antide-
pressant effect may involve OR 𝛽 rather than OR 𝛼 [29].
Furthermore, genistein may regulate serotonergic pathway
under stressful conditions. In their study, genistein decreased
serotonin turnover ratio (5-HIAA/5-HT), indicating sero-
tonin level increased in hippocampus.Monoamine-oxidaseA
(MAO-A) is amitochondrial enzyme involved inmetabolism
of monoamines such as dopamine and serotonin. MAO-A
inhibitors are effective in treatment of depression. Hence
genistein may regulate activity of MAO-A in brain [30].
Oxidative stresses are correlated with the pathophysiology
of depression [31]. Therefore it suggests that antioxidant
property of genisteinmay contribute to its antidepressant-like
activity.
Importantly, genistein in moderation is well tolerated
[32, 33]. Larger doses of genistein have been demonstrated
to increase apoptosis and may be contraindicated in cancer
regimens. In clinical trials, gastrointestinal adverse effects are
the most common reason for treatment discontinuation. In
addition, there is no change in endometrial thickness and
breast density with daily administration of 54mg of genistein
for 3 years in postmenopausal women [32].
To our knowledge, the current study first time demon-
strates the additive and synergistic effect of genistein in com-
bination with antidepressant drug. Genistein (10mg/kg) can
be an adjunctive treatment with amitriptyline (10mg/kg) for
patients resistant to the conventional treatments. Addition-
ally, genistein (10mg/kg) in combination with subeffective
dose of amitriptyline (5mg/kg)may reduce the dose and thus
the side effects of antidepressant drugs. This is important in
cases of childhood depression or postnatal depression where
safety of medication is being questioned.
Our results constitute further studies concerning the
locomotor activity. Although previous studies have demon-
strated that amitriptyline and genistein do not affect locomo-
tor activity in rodents, locomotor activity shall be assessed
to distinguish antidepressants from psychostimulants to pre-
vent false positive results [34]. Further investigations, for
instance, measurement of corticosterone, pharmacokinetic
studies, and toxicology assessments, are recommended for
better understanding of the observed phenomenon.
5. Conclusions
In summary, the present study supports the hypothesis that
genistein enhanced the antidepressant effect of amitriptyline
in tail suspension test. These findings might be important
in the development of new treatment strategies and in the
medical practice. The synergistic effect could mean a higher
response for those with treatment-resistant depression and
reduces the magnitude of side effects with low dose of
antidepressant drugs.
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